JBC Oz Biosciences

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M602627200 on June 19, 2006

J. Biol. Chem., Vol. 281, Issue 33, 23425-23435, August 18, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/33/23425    most recent
M602627200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sethi, G.
Right arrow Articles by Aggarwal, B. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sethi, G.
Right arrow Articles by Aggarwal, B. B.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Indirubin Enhances Tumor Necrosis Factor-induced Apoptosis through Modulation of Nuclear Factor-{kappa}B Signaling Pathway*

Gautam Sethi{ddagger}, Kwang Seok Ahn{ddagger}, Santosh K. Sandur{ddagger}, Xin Lin§, Madan M. Chaturvedi{ddagger}1, and Bharat B. Aggarwal{ddagger}2

From the {ddagger}Cytokine Research Laboratory, Department of Experimental Therapeutics and §Molecular and Cellular Oncology, the University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Although indirubin is known to exhibit anti-cancer and anti-inflammatory activities, very little is known about its mechanism of action. In this study, we investigated whether indirubin mediates its effects through interference with the NF-{kappa}B pathway. As examined by the DNA binding of NF-{kappa}B, we found that indirubin suppressed tumor necrosis factor (TNF)-induced NF-{kappa}B activation in a dose- and time-dependent manner. Indirubin also suppressed the NF-{kappa}B activation induced by various inflammatory agents and carcinogens. Further studies showed that indirubin blocked the phosphorylation and degradation of I{kappa}B{alpha} through the inhibition of activation of I{kappa}B{alpha} kinase and phosphorylation and nuclear translocation of p65. NF-{kappa}B reporter activity induced by TNFR1, TNF receptor-associated death domain, TRAF2, TAK1, NF-{kappa}B-inducing kinase, and IKKbeta was inhibited by indirubin but not that induced by p65 transfection. We also found that indirubin inhibited the expression of NF-{kappa}B-regulated gene products involved in antiapoptosis (IAP1, IAP2, Bcl-2, Bcl-xL, and TRAF1), proliferation (cyclin D1 and c-Myc), and invasion (COX-2 and MMP-9). This correlated with enhancement of the apoptosis induced by TNF and the chemotherapeutic agent taxol in human leukemic KBM-5 cells. Indirubin also suppressed cytokine-induced cellular invasion. Overall, our results indicate that anti-cancer and anti-inflammatory activities previously assigned to indirubin may be mediated in part through the suppression of the NF-{kappa}B activation pathway.


Received for publication, March 21, 2006 , and in revised form, June 12, 2006.

* This work was supported by a grant from the Clayton Foundation for Research (to B. B. A.), National Institutes of Health PO1 Grant CA91844 (to B. B. A.), and National Institutes of Health SPORE Grant P50CA97007 (to B. B. A.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 On leave from the Dept. of Zoology, University of Delhi, Delhi-110007, India.

2 Ransom Horne, Jr., Professor of Cancer Research. To whom correspondence should be addressed: Cytokine Research Laboratory, Dept. of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030. Tel.: 713-792-3503; Fax: 713-794-1613; E-mail: aggarwal{at}mdanderson.org.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Mol Cancer ResHome page
G. Sethi, K. S. Ahn, and B. B. Aggarwal
Targeting Nuclear Factor-{kappa}B Activation Pathway by Thymoquinone: Role in Suppression of Antiapoptotic Gene Products and Enhancement of Apoptosis
Mol. Cancer Res., June 1, 2008; 6(6): 1059 - 1070.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
G. Sethi, K. S. Ahn, B. Sung, and B. B. Aggarwal
Pinitol targets nuclear factor-{kappa}B activation pathway leading to inhibition of gene products associated with proliferation, apoptosis, invasion, and angiogenesis
Mol. Cancer Ther., June 1, 2008; 7(6): 1604 - 1614.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Orlandi, A. Francesconi, M. Marcellini, A. Di Lascio, and L. G. Spagnoli
Propionyl-L-carnitine Reduces Proliferation and Potentiates Bax-related Apoptosis of Aortic Intimal Smooth Muscle Cells by Modulating Nuclear Factor-{kappa}B Activity
J. Biol. Chem., February 16, 2007; 282(7): 4932 - 4942.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.